Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 6/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650898 | 0.88 | PTPN1 (0.43) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL652694 | 0.87 | GSK3B (0.47) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL651730 | 0.82 | MAPT (0.35) | HPGDPOLBPKMALOX12MAPT | |
| SCHEMBL10176414 | 0.76 | HPGD (0.53) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL653362 | 0.74 | MAPT (0.45) | HPGDPOLBCDC25BMAPTRAB9A | |
| SCHEMBL650134 | 0.74 | AKR1B1 (0.39) | HPGDPOLBMAPTTDP1 | |
| SCHEMBL653944 | 0.74 | MAPT (0.38) | POLBCDC25BMAPTNPC1RAB9A | |
| SCHEMBL650076 | 0.73 | MAPT (0.44) | HPGDPOLBMAPTTDP1 | |
| SCHEMBL649047 | 0.73 | MAPT (0.41) | POLBCDC25BMAPTNPC1RAB9A | |
| SCHEMBL650769 | 0.72 | MAPT (0.39) | HPGDPOLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | HPGD 3970/4885POLB 2967/4885PKM 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.